BIVI Swine Division Adds Two Experienced Sales Representatives

Industry veterans Randy Anderson and Thad Hinkle have joined the Swine Division sales and marketing team at Boehringer Ingelheim Vetmedica, Inc. (BIVI).

“One of our top priorities is to ensure our customer service always keeps pace with the expansion of our product portfolio,” said Greg Lewis, regional manager, Swine Division, BIVI. “Randy and Thad both impressed us with their exceptional people skills, swine health knowledge and willingness to go the extra mile to help veterinarians and producers solve problems.”

Anderson will focus on strategic and key accounts. He joins BIVI from Genesus Genetics Inc., where he was general manager for the United States and led a national account team that managed 50 top accounts. His previous industry experience includes work at Novus International, where he served as senior director of North America, director of North America Livestock Business and national sales manager for the Pork Business Team. Anderson earned a Bachelor of Science degree in agriculture communications from Illinois State University.

Hinkle joins BIVI as a sales representative working with strategic accounts. His most recent industry position was operations manager for Cargill Pork. He also served several key positions including technical service manager, production manager and multiplication production manager. He also worked as field manager technician at Tyson Foods. Hinkle graduated from Arkansas Tech University with a Bachelor of Science in agriculture business and minor in animal science.

“We are excited to welcome Thad and Randy to our team,” said Lewis. “Even more importantly, both have extensive swine industry experience and expertise that will be of benefit to our customers.”

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information, visit